Insights From Long-Term Follow-Up of the GMMG-HD6 Trial in MM
Addition of elotuzumab to standard therapy in transplant-eligible patients with MM did not improve PFS or OS in the long-term follow-up of the GMMG-HD6 trial.
Dec 4, 2024
MEETING BRIEF
ASH 2024 – MM
The latest news from ASH 2024 focused on multiple myeloma (MM) including abstracts, features, and helpful conference information.
The Role of Noncoding RNAs in the Bone Marrow Microenvironment of MM
The Role of Noncoding RNAs in the Bone Marrow Microenvironment of MM
“This study reveals distinct immune subpopulations associated with specific myeloma cell genotypes and highlights the central role of ncRNAs in modulating the phenotypic and functional states of both malignant and non-malignant cells in the MM BMME,” the authors concluded.
Will You Be Attending This Session at ASH?
Will You Be Attending This Session at ASH?
Will you be attending “Newly Diagnosed Multiple Myeloma: Many Choices and More Questions” on Saturday, December 7?
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
